Li Shen, Yue Wu, Jin Liu, Lu Ye, Jing Yang, Xiao Wu, Hong Xu
{"title":"The HIV-1 Transmitted Drug Resistance in Newly Confirmed and ART-Naïve HIV-1-Infected MSM in Zhenjiang City, Jiangsu, China.","authors":"Li Shen, Yue Wu, Jin Liu, Lu Ye, Jing Yang, Xiao Wu, Hong Xu","doi":"10.1089/aid.2025.0032","DOIUrl":null,"url":null,"abstract":"<p><p>Estimating the prevalence and characterizing the HIV-1 transmitted drug resistance (TDR) are crucial for the prevention and control of HIV/AIDS. However, there are limited data currently on TDR among men who have sex with men (MSM) in Zhenjiang, Jiangsu, a high-risk population for drug resistance. We conducted a retrospective analysis among the newly diagnosed and antiretroviral therapy (ART)-naive HIV-1-infected MSM in Zhenjiang, 2012-2018. We analyzed the HIV-1 subtypes, TDR prevalence, TDR-associated mutations, and predicted drug sensitivity. Among these 192 participants, CRF01_AE (50.0%) and CRF07_BC (34.9%) were the predominant HIV-1 strains, with an increasing diversity of circulating subtypes (<i>p</i> < .05). A total of nine patients infected with CRF01_AE exhibited one or more TDR mutations, including 3.6% for Protease Inhibitor (PI)-related mutations, 1.0% for NRTI-related mutations and 1.0% for NNRTI-related mutations. The most common mutation was M46L/I for PIs. Notably, TDR prevalence showed an upward trend from 2012 to 2018, with an average of 4.7%. The gradually diversified subtypes, the increased TDR prevalence, and the potential risk of transmitting drug-resistant strains to the general population highlight the necessity of TDR monitoring in MSM. This will be beneficial for the prevention and control of HIV/AIDS in Zhenjiang.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/aid.2025.0032","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Estimating the prevalence and characterizing the HIV-1 transmitted drug resistance (TDR) are crucial for the prevention and control of HIV/AIDS. However, there are limited data currently on TDR among men who have sex with men (MSM) in Zhenjiang, Jiangsu, a high-risk population for drug resistance. We conducted a retrospective analysis among the newly diagnosed and antiretroviral therapy (ART)-naive HIV-1-infected MSM in Zhenjiang, 2012-2018. We analyzed the HIV-1 subtypes, TDR prevalence, TDR-associated mutations, and predicted drug sensitivity. Among these 192 participants, CRF01_AE (50.0%) and CRF07_BC (34.9%) were the predominant HIV-1 strains, with an increasing diversity of circulating subtypes (p < .05). A total of nine patients infected with CRF01_AE exhibited one or more TDR mutations, including 3.6% for Protease Inhibitor (PI)-related mutations, 1.0% for NRTI-related mutations and 1.0% for NNRTI-related mutations. The most common mutation was M46L/I for PIs. Notably, TDR prevalence showed an upward trend from 2012 to 2018, with an average of 4.7%. The gradually diversified subtypes, the increased TDR prevalence, and the potential risk of transmitting drug-resistant strains to the general population highlight the necessity of TDR monitoring in MSM. This will be beneficial for the prevention and control of HIV/AIDS in Zhenjiang.
期刊介绍:
AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes.
AIDS Research and Human Retroviruses coverage includes:
HIV cure research
HIV prevention science
- Vaccine research
- Systemic and Topical PreP
Molecular and cell biology of HIV and SIV
Developments in HIV pathogenesis and comorbidities
Molecular biology, immunology, and epidemiology of HTLV
Pharmacology of HIV therapy
Social and behavioral science
Rapid publication of emerging sequence information.